Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke

• Status: Completed
• Trial end date: 2021-10-02
• Target enrollment: 0
• Participant gender: All

Summary

Pneumonia is a major cause of mortality and morbidity in patients with acute stroke fed via nasogastric tubes and may be because of vomiting and gastro-esophageal regurgitation. The aim of the study was to assess whether regular treatment with metoclopramide, a D2-receptor antagonist with antiemetic and gastric prokinetic actions, could reduce the rate of pneumonia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University
• Treatments: Metoclopramide

Criteria

Inclusion Criteria:

1. Patients of either gender.

2. Patients within 7 days of acute ischemic or hemorrhagic stroke confirmed by computed tomographic scan of the brain who required nasogastric feeds for >24 hours, and could be recruited within 48 hours of NGT insertion

3. Age above 13 years.

Exclusion Criteria:

• Patients with aspiration pneumonia at the time of presentation.

• Patients with a history of chronic neurodegenerative diseases that could affect swallowing (e.g. Parkinson disease and motor neuron disease)

• Poor postural control (unable to sit up for swallowing assessment).

• Esophageal disorders,

• Contraindications to metoclopramide.